Posts

Posted on

ADCO selects Rackspace Technology to manage cloud native journey with multicloud enhancements

LONDON, March 10, 2021 (GLOBE NEWSWIRE) — Rackspace Technology™ (NASDAQ: RXT), a leading end-to-end multicloud technology solutions company, has been selected by ADCO Umweltdienste Holding GmbH to spearhead its cloud native journey using Amazon Web Services (AWS), VMware and app modernisation.

The ADCO Group is the global market leader in the field of mobile sanitary solutions and an acknowledged specialist in the rental of sanitary containers and temporary room solutions. As a modern service provider, the ADCO Group sets the standards in hygiene and quality, offering an extensive service and product portfolio under the TOI TOI® and DIXI® brands. ADCO is to reshape its IT strategy for improved resiliency, sustainability and cost optimisation. The transformation will directly benefit and improve its business processes and governance. And, by fully exploiting the potential to become cloud native, it aims to sustain its position as a leader in its market.

With Rackspace Technology, ADCO will transform its business-critical on-premise data centres with a migration to AWS and leverage VMware cloud services together with native AWS services. In addition it has also initiated a move to Office 365.

As part of this five-year deal, the migration will start in Germany and will expand globally across its other global markets.

“Our cloud native journey not only underpins our commitment to providing continued innovation for the industry, but allows us to gain future growth,” said Adriaan Verkerk, CIO, ADCO Umweltdienste Holding GmbH.

“This would only be possible with an expert partner like Rackspace Technology who has already shown deep understanding of our business needs and demonstrated a proof of concept that fits perfectly with our corporate goals.”

Jürgen Stauber, GM for DACH region at Rackspace Technology, added: “Increasingly, customers like ADCO are realising the benefits of multicloud approaches. With our support, ADCO will not just transform its technology, but enhance its organisational and operational processes to help it to move towards Containers, Serverless and DevOps with agile methodologies and governance to ensure its desired business outcomes become a reality.”

About Rackspace Technology


Rackspace Technology
 is a leading end-to-end multicloud technology services company. We can design, build and operate our customers’ cloud environments across all major technology platforms, irrespective of technology stack or deployment model. We partner with our customers at every stage of their cloud journey, enabling them to modernize applications, build new products and adopt innovative technologies.

Media Contact

Devika Mistry
EMEA Rackspace Technology Corporate Communications
[email protected]



Posted on

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. – ACAD

PR Newswire

NEW YORK, March 10, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company”) (NASDAQ: ACAD).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether ACADIA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 


[Click here for information about joining the class action]
 

On March 8, 2021, post-market, Acadia issued a press release providing a regulatory update on the Company’s supplemental New Drug Application (“NDA”) for Pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis, disclosing “that the Company received a notification from the U.S. Food and Drug Administration (FDA) on March 3, 2021, stating that, as part of its ongoing review of the Company’s supplemental New Drug Application (sNDA), the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time.”  Acadia advised that “[t]he notification does not specify the deficiencies identified by the FDA and there has been no clarification by the FDA at this time.”  On this news, Acadia’s stock price fell $20.76 per share, or 45.35%, to close at $25.02 per share on March 9, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:

Robert S. Willoughby

Pomerantz LLP
[email protected]

Cision View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-acadia-pharmaceuticals-inc—acad-301244139.html

SOURCE Pomerantz LLP

Posted on

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XL Fleet Corporation – XL

PR Newswire

NEW YORK, March 10, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of XL Fleet Corporation (“Gannett” or the “Company”)(NYSE: XL).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether XL Fleet and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 


[Click here for information about joining the class action]
 

On March 3, 2021, Muddy Waters published a report on the Company entitled “More SPAC Trash.”  Citing interviews with former employees, the Muddy Waters report asserted that XL Fleet’s management systemically inflates the Company’s backlog and grossly overstates XL Fleet’s customer base, with at least 18 of 33 touted customers being inactive.  The Muddy Waters report also alleges that the Company significantly exaggerates sales projections and overstates its technological capabilities. 

On this news, XL Fleet’s stock price fell $2.09 per share, or 13.1%, to close at $13.86 per share on March 3, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP
[email protected] 
888-476-6529 ext. 7980

Cision View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-xl-fleet-corporation—xl-301244130.html

SOURCE Pomerantz LLP

Posted on

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Baker Hughes Company – BKR

PR Newswire

NEW YORK, March 10, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Baker Hughes Company (“Baker Hughes” or the “Company”) (NYSE:  BKR).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.

The investigation concerns whether Baker Hughes and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 


[Click here for information about joining the class action]
 

On February 25, 2021, post-market, Baker Hughes filed its annual report with the U.S. Securities and Exchange Commission (“SEC”).  In the report, Baker Hughes revealed that, in December of 2020, the SEC had notified Baker Hughes of an investigation into the Company “related to its books and records and internal controls regarding sales of its products and services in projects impacted by U.S. sanctions.”  Baker Hughes also revealed that the Company had initiated an internal review “regarding internal controls and compliance related to U.S. sanctions requirements.”  On this news,

Baker Hughes’s stock price fell $0.25 per share, or 1.01%, to close at $24.48 per share on February 26, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:

Robert S. Willoughby

Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

 

Cision View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-baker-hughes-company—bkr-301244131.html

SOURCE Pomerantz LLP

Posted on

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CytoDyn Inc. – CYDY

PR Newswire

NEW YORK, March 10, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of  CytoDyn Inc. (“CytoDyn” or the “Company”) (OTCMKTS: CYDY).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether CytoDyn and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 


[Click here for information about joining the class action]
 

On March 5, 2021, CytoDyn issued a press release providing an update on its product “Vyrologix (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications.”  The press release stated, in part, that “the Phase 3 trial of leronlimab for the treatment of severe-to-critical patients with COVID-19 demonstrated continued safety, substantial improvement in the survival rate, and faster hospital discharge in critically ill COVID-19 patients.”  Although the press release touted purportedly positive results, industry observers and analysts quickly characterized the Company’s press release as misleading.  For example, on March 8, 2021, Seeking Alpha published an article by Paul Santos entitled “CytoDyn: Parsing Failure.”  The article asserted that CytoDyn’s “leronlimab Phase 3 trial on COVID-19 severe-to-critical patients failed . . . to meet both its primary endpoint and all secondary endpoints with any statistical significance” and described the Company as having effectively “buried” the results in its press release.  Santos noted that “[a] normal biotech company would have stated this clearly, both in its PR titles and in their text bodies. CytoDyn, however, did something else.” 

As the market digested the actual significance of CytoDyn’s announcement, the Company’s stock price fell $1.70 per share, or 41.98%, over the following two trading sessions, closing at $2.35 per share on March 9, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:

Robert S. Willoughby

Pomerantz LLP
[email protected]

Cision View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-cytodyn-inc—cydy-301244161.html

SOURCE Pomerantz LLP

Posted on

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA, Inc. – IMRA

PR Newswire

NEW YORK, March 10, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of IMARA, Inc. (“IMARA” or the “Company”) (NASDAQ: IMRA).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether IMARA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 


[Click here for information about joining the class action]

On or around March 11, 2020, Imara conducted its initial public offering (“IPO”), selling 4,700,000 shares of common stock priced at $16.00 per share.  On March 5, 2021, Imara reported its financial results for the year ended December 31, 2020, which included a net loss of $49.2 million, compared to a net loss of $23.5 million for the prior year.  On this news, Imara’s stock price fell $2.34 per share, or 19.01%, to close at $9.97 per share on March 5, 2021.  Since the IPO, Imara’s stock price has closed as low as $9.54 per share, representing a decline of over 40% from the offering price.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:

Robert S. Willoughby

Pomerantz LLP
[email protected]

 

Cision View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-imara-inc–imra-301244126.html

SOURCE Pomerantz LLP

Posted on

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Xeris Pharmaceuticals, Inc. – XERS

PR Newswire

NEW YORK, March 10, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Xeris Pharmaceuticals, Inc. (“Xeris” or the “Company”) (NASDAQ: XERS).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Xeris and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 


[Click here for information about joining the class action]

On or around June 20, 2018, Xeris conducted its initial public offering (“IPO”), selling 5,700,000 shares of common stock priced at $15.00 per share.  On March 9, 2021, Xeris issued a press release announcing its fourth quarter and full year 2020 results.  Among other results, Xeris reported fourth quarter GAAP earnings per share of $0.41, missing consensus estimates by $0.01, and revenue of $7.09 million, missing consensus estimates by $1.82 million.  On this news, Xeris’s stock price fell $0.11 per share, or 2.33%, to close at $4.61 per share on March 9, 2021.  Since the IPO, Xeris’s stock price has closed as low as $1.49 per share, representing a decline of more than 90% from the offering price.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP 
[email protected] 
888-476-6529 ext. 7980

Cision View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-xeris-pharmaceuticals-inc—xers-301244124.html

SOURCE Pomerantz LLP

Posted on

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Root, Inc. – ROOT

PR Newswire

NEW YORK, March 10, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Root, Inc. (“Root” or the “Company”) (NASDAQ: ROOT).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Root and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 


[Click here for information about joining the class action]
 

On or around October 27, 2020, Root conducted its initial public offering (“IPO”), selling 26.8 million shares of common stock priced at $27.00 per share.  Then, on March 9, 2021, BofA Securities analyst Joshua Shanker initiated coverage of Root with an “Underperform” rating on the premise that the Company is unlikely to be cash flow positive until 2027, finding that Root “will require not insignificant cash infusions from the capital markets to bridge its cash flow needs.” 

On this news, Root’s stock price fell $0.18 per share, or 1.46%, to close at $12.17 per share on March 9, 2021, representing a total decline of 54.93% from the offering price.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:

Robert S. Willoughby

Pomerantz LLP
[email protected]

Cision View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-root-inc—root-301244123.html

SOURCE Pomerantz LLP

Posted on

FPT to Provide SAP AMS Service for E.ON Across 8 Countries in Europe

FPT to Provide SAP AMS Service for E.ON Across 8 Countries in Europe

ESSEN, Germany–(BUSINESS WIRE)–
FPT Europe – a subsidiary of FPT Corporation, the global technology service provider, today announced that FPT Europe and E.ON have concluded a 3 -year-contract for SAP related services. FPT will provide Application Managed Service (AMS) for three systems of E.ON’s ERP, including an S/4-based one. These systems are currently supporting 16,000 users from 8 countries across Europe.

“With this initiative we will optimize our current sourcing mix in order to achieve not only cost savings but to consolidate suppliers in the area of application maintenance and support. We see this as an enabler for service and process harmonization and integration of E.ON and innogy IT processes. Furthermore, the new setup will strengthen the BizDevOps model within E.ON by closely integrating external resources into cross-functional teams,” explained Mr. Wendiggensen, Vendor and IT Transformation Manager at E.ON Digital Technology GmbH, the main objectives of the contract.

The contract marks an important milestone of the cooperation for both sides. Since 2020, FPT has helped E.ON to increase cost efficiency of their SAP CORE domain with the ongoing S/4 projects.

“We are pleased to serve our client in one of their business-critical domains. It shows that our long-term strategic partnership is really a win-win collaboration in mutual benefit for both sites. We will continue to develop our strong presence in SAP domain as this belongs to our long-term digital transformation strategy,” said Emil Figura, FPT Executive Account Manager for E.ON.

FPT has more than 20 years of experience delivering services related to SAP. With a pool of more than 300 functional consultants and 250 technical consultants, the company has successfully implemented and rolled out SAP systems for its customers in Southeast Asia, Japan and Europe.

FPT’s SAP S/4HANA provides enterprises with a wide range of services including development, implementation, roll out and application managed service. FPT owned solutions for SAP Migration, SAP Customization, SAP Rollout and SAP Automation Test, backed by the company’s methodology and framework help other companies to maximize their business value of adopting SAP S/4HANA.

ABOUT FPT

FPT Europe, based in Essen, Germany is a part of FPT Corporation – a technology and IT services provider headquartered in Vietnam with nearly US$2 billion in revenue and 36,000 employees. Being a pioneer in digital transformation, the company delivers world-class services in Smart factory, Digital platforms, RPA, AI, IoT, Data Analytics, Mobility, Cloud, Managed Services, Testing. FPT Software has served over 700 customers worldwide, 100 of which are Fortune 500 companies in the industries of Aerospace & Aviation, Automotive, Banking and Finance, Communications, Media and Services, Logistics & Transportation, Utilities, Consumer Packaged Goods, Healthcare, Manufacturing, Public sector, Technology and so on. Established in 2012, FPT Europe has become technology partners of 50 leading companies including Siemens, RWE, Allianz, Schaeffler, Airbus, Carlsberg and many more. For other information, please visit: www.fpt-europe.de

ABOUT E.ON

E.ON is an international private energy company based in Essen that focuses on the business areas of energy networks and customer solutions. As one of the largest energy companies in Europe, E.ON takes a leading role in shaping a green, digital and decentralized energy world. Around 75,000 employees develop and sell products and solutions for private, commercial and industrial customers. More than 50 million customers purchase electricity, gas, digital products or solutions for electromobility, energy efficiency and climate protection from E.ON. As an innovation leader, E.ON offers its customers the latest technological solutions and promotes cross-sector partnerships in the energy sector and beyond. More information at www.eon.com

Linh Pham

Head of Marketing and Communications

FPT Europe

Email: [email protected]

KEYWORDS: Germany Europe Viet Nam Asia Pacific

INDUSTRY KEYWORDS: Software Networks Internet Hardware Data Management Technology Mobile/Wireless Other Technology

MEDIA:

Logo
Logo
Posted on

Ellume and Cambridge Consultants Collaborate on Core Technology Behind Ellume’s Rapid Antigen COVID-19 Test

Cambridge Consultants developed the ground-breaking optics technology powering Ellume’s FDA authorized COVID-19 Home Test

CAMBRIDGE, United Kingdom and BRISBANE, Australia, March 10, 2021 (GLOBE NEWSWIRE) — Today, digital diagnostics company Ellume highlights the revolutionary technology created in partnership with global product development and technology consultancy firm, Cambridge Consultants, part of the Capgemini Group. Together, the two companies have developed a next-generation, multi-component reader that combines optics, electronics and software, and powers the core technology behind the Ellume COVID-19 Home Test. Ellume’s test is the first rapid self-test for COVID-19 detection granted Emergency Authorization Use by the U.S. FDA for both asymptomatic and symptomatic use without a prescription. In February, Ellume announced a $231.8 million agreement with the U.S. government, including the delivery of 8.5 million Ellume COVID-19 Home Tests to support the U.S. government’s pandemic response and the establishment of Ellume’s first U.S. manufacturing facility.

The success of this test can be attributed in large part to the several years of work from the global, multidisciplinary team at Cambridge Consultants to create an ultrasensitive, optoelectronic detection system that is used across all of Ellume’s diagnostics products. This technology includes a sensitive, but inexpensive reader to detect and interpret the near-infrared photons emitted from a quantum dot captured at the test zones of a lateral flow test strip. The reader, coupled with Ellume’s supercharged fluorescent immunochromatography, delivers world-leading specificity and sensitivity.

“The Cambridge Consultants team’s dedicated work and novel approach helped us to create a highly accurate and quantitative digital immunoassay that is also affordable, robust and simple to use – the crucial elements at the heart of successful at-home testing,” said Dr. Sean Parsons, CEO and founder of Ellume. “At-home, rapid testing is key to slowing the spread of COVID-19 in the coming months. Without Cambridge Consultants and their continued partnership over the years, we wouldn’t have been able to achieve technical success.”

“Dr. Parsons came to us with a big challenge and a strong vision that together, we faced head on. At the time, we never knew the impact it would have on the COVID-19 epidemic,” said Nick Hawson, Senior Vice President for MedTech (US West) at Cambridge Consultants. “We’ve created a strong, long-lasting partnership with Ellume rooted in collaboration and innovation, and we hope we continue to find ways to use this technology in digital diagnostics and continue our impact on global health.”

The impact of this technology extends beyond the Ellume COVID-19 Home Test, and even beyond the COVID-19 pandemic. Using the same core technology that Cambridge Consultants helped develop, Ellume has created two other COVID-19 diagnostic tests in the past year – the QIAREACH™ COVID-19 antigen and antibody tests for the laboratory market and ellume·lab COVID-19 serology and antigen tests for healthcare professionals (to be launched later in 2021). The company has also leveraged the core sensing breakthrough in its core technology for its rapid home flu test and diagnostic assay for tuberculosis. Not only are rapid tests like Ellume’s integral to stopping the spread of the COVID-19 virus, but they could also play a critical role in tackling future pandemics and other infectious diseases across the globe.

About Cambridge Consultants

Cambridge Consultants develops breakthrough products, creates and licenses intellectual property, and provides business consultancy in technology-critical issues for clients worldwide. For more than 60 years, the company has been helping its clients turn business opportunities into commercial successes, whether they are launching first-to-market products, entering new markets or expanding existing markets through the introduction of new technologies. With a team of more than 900 staff, including engineers, scientists, mathematicians and designers, in offices in Cambridge (UK), Boston (USA), Tokyo and Singapore, Cambridge Consultants offers solutions across a diverse range of industries including medical and life science, industrial and energy, consumer and retail, and communications and infrastructure. For more information, visit: www.cambridgeconsultants.com

Cambridge Consultants is part of Capgemini Invent, the innovation, consulting and transformation brand of the Capgemini Group. Capgemini Invent helps CxOs envision and build what’s next for their organisations. Located in more than 30 offices and 25 creative studios around the world, its 7,000+ strong team combines strategy, technology, data science and creative design with deep industry expertise and insights, to develop new digital solutions and business models of the future. Capgemini Invent is an integral part of Capgemini, a global leader in partnering with companies to transform and manage their business by harnessing the power of technology. The Group is guided everyday by its purpose of unleashing human energy through technology for an inclusive and sustainable future. It is a responsible and diverse organisation of 270,000 team members in nearly 50 countries. With its strong 50 year heritage and deep industry expertise, Capgemini is trusted by its clients to address the entire breadth of their business needs, from strategy and design to operations, fueled by the fast evolving and innovative world of cloud, data, AI, connectivity, software, digital engineering and platforms. The Group reported in 2020 global revenues of €16 billion.

Get the Future You Want | www.capgemini.com

About Ellume

Ellume is at the forefront of accurate, rapid and accessible testing that is integral to today’s COVID-19 response and will help ensure the world is prepared for the next infectious disease pandemic. Ellume is a digital diagnostics company that develops, manufactures, and commercializes high-performance, connected products for healthcare professionals and consumers. Ellume’s key focus is on the detection of common infectious diseases which affect the global population across all diagnostic settings; at-home, point-of-care and in-laboratory. Ellume’s suite of products differ from conventional diagnostics through performance, digital connectivity, actionability and simplicity. Its novel detection technology is powered by unique quantum dot nanoparticles and integrates optics, electronics, biologics and software into an intuitive and high-performance digital platform. Ellume has a global consumer health partnership with GlaxoSmithKline, a global COVID-19 and latent TB partnership with QIAGEN, and a range of professional products under its ellume·lab brand. Ellume is committed to developing high-quality digital diagnostics that the world can rely on in a health crisis. Further information can be found at ellumehealth.com.


Media Inquiries



For UK


Ketchum for Cambridge Consultants
E:[email protected]


For U.S.

For Australian
LaunchSquad for Ellume
E: [email protected]
M: +1 570 417 3644		 Patrick Condren, Ellume
E: [email protected]
M: +61 405 186 630

Photos accompanying this announcement are available at: 

https://www.globenewswire.com/NewsRoom/AttachmentNg/40fdc492-b89d-493d-872b-b89d57cae1db

https://www.globenewswire.com/NewsRoom/AttachmentNg/a0fe9d36-a53b-453a-a068-ef24f487165e

https://www.globenewswire.com/NewsRoom/AttachmentNg/584c2a14-2ee2-4cb9-9b0b-050ed57f8cb0